Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionExchange Traded Concepts, Llc
Latest Disclosed Ownership13,875 shares
Latest Disclosed Value $ 6,195,742
Exchange Traded Concepts, Llc reports 15.38% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 15, 2026 - Exchange Traded Concepts, Llc filed a 13F-HR form disclosing ownership of 13,875 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $6,195,742 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 14, 2026 disclosing 12,025 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 15.38% during the quarter. The current value of the position is $6,199,766 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,875 1,850 15.38 6,196 13.65 0.0211
2026-01-14 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,025 1,874 18.46 5,452 37.13 0.0415
2025-10-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,151 7,565 292.54 3,976 245.35 0.0338
2025-07-10 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,586 -37 -1.41 1,151 -9.44 0.0141
2025-04-17 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,623 -322 -10.93 1,272 7.26 0.0218
2025-01-21 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,945 -13 -0.44 1,186 -13.82 0.0236
2024-10-10 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,958 -2,355 -44.33 1,376 -44.78 0.0322
2024-08-13 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,313 -128 -2.35 2,490 9.50 0.0630
2024-04-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,441 -2,318 -29.87 2,274 -27.97 0.0587
2024-01-05 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,759 -1,371 -15.02 3,157 -0.54 0.0844
2023-10-18 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,130 799 9.59 3,175 8.29 0.0899
2023-07-20 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,331 -1,926 -18.78 2,932 -9.29 0.0722
2023-04-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,257 1,761 20.73 3,232 31.72 0.0886
2023-01-27 2022-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 8,496 -2,390 -21.95 2,453 -22.18 0.0703
2023-01-18 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,496 -2,390 2 0.0703
2022-10-07 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,886 -867 -7.38 3,152 -4.83 0.1032
2022-07-20 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,753 -2,299 -16.36 3,312 -9.68 0.0963
2022-04-26 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,052 1,942 16.04 3,667 37.91 0.0736
2022-01-13 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,110 -3,346 -21.65 2,659 -5.17 0.0515
2021-10-18 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 15,456 -11,217 -42.05 2,804 -47.86 0.0716
2021-07-30 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,673 15,666 142.33 5,378 127.40 0.1701
2021-04-20 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,007 4,132 60.10 2,365 45.54 0.0885
2021-01-19 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,875 4,468 185.63 1,625 148.09 0.0754
2020-10-30 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,407 1,059 78.56 655 67.52 0.0371
2020-07-15 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,348 819 154.82 391 210.32 0.0649
2020-04-14 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 529 101 23.60 126 34.04 0.0681
2020-01-22 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 428 428 94 0.0196
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.